This study is testing a new oral medication called APG-2575 for people with certain blood cancers (hematologic malignancies), including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma. The main goal is to find the highest dose of APG-2575 that can be given safely without causing too many side effects. This is a Phase 1 study, meaning it's one of the first times this drug is being tested in people. You may be eligible if you are at least 18 years old and have one of the specified blood cancers. The study is currently unclear on its recruitment status and plans to enroll about 90 participants.

Study design

This is an open-label, single-arm Phase 1 study, meaning all participants will receive APG-2575 and both you and the study team will know which treatment you are getting. The study aims to enroll about 90 participants.

What's involved

APG-2575 will be taken as an oral tablet once daily for four consecutive weeks per cycle. The dose may be increased in subsequent cycles.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, Maximum Tolerated Dose (MTD), is measured at 28 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.